$ASIX

AdvanSix (ASIX) Offsets Rising Costs With Pricing As Fertilizer Demand Softens

AdvanSix (NYSE:ASIX) reported Q2 sales of $421 million, up about 3% y/y, but adjusted EBITDA fell $24 million to $32 million and adjusted EPS dropped to $0.19. The company said $72 million higher raw material costs were offset by pricing, while fertilizer demand softened, driving unfavorable volume impacts. Guidance includes ammonia volume growth plans for 2026.

Original reporting
Published Aug 18, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AdvanSix (ASIX) Offsets Rising Costs With Pricing As Fertilizer Demand Softens — source image
Decision brief

The 30-second read

$ASIXNeutralMed
01

Why it matters

The key trade is whether 2026 ammonia volume growth, conversion progress, and carbon-credit support can overcome volume weakness and sulfur-driven cost sensitivity, affecting margin and cash-flow forecasts.

02

Market read

Quantified cost and demand drivers (pricing +18% vs volume -15%, $72M raw-material headwind offset, $17M unfavorable volume impact) provide a concrete basis to reprice near-term margin risk and 2026 cash-flow expectations.

03

What to watch

The article flags a supplier pipeline inspection-driven turnaround shift and a fertilizer pre-buy working-capital tailwind; traders may underweight how these timing items reverse in subsequent quarters.

Relevance 7/10Novelty 6/10Timing: post-earnings, for positioning into 2H 2026 cash-flow expectations

Background

AdvanSix is navigating fertilizer-cycle demand softness while managing raw-material and sulfur cost spikes through pricing and operational mix improvements.

Company-level read

Ticker impact

$ASIXNeutralMedium confidence
Context

AdvanSix reported Q2 sales up 3% but adjusted EBITDA and EPS fell, citing a $72M raw-material cost jump and softer fertilizer demand.

Expected impact

Near-term bias depends on whether managements 2026 ammonia volume growth and USDA grant can offset demand softness and sulfur-cost volatility.

Evidence & confidence

The article provides quantified drivers (pricing vs volume, cost headwinds, sulfur marker sensitivity) plus forward-looking volume and cash-flow commentary, which can move estimates and positioning.

Market effects

Highlights fertilizer input cost volatility (benzene/propylene, sulfur) and how pricing pass-through may not fully protect volumes when crop prices weaken.

US-focused fertilizer demand and domestic granular ammonium sulfate conversion mix could influence regional ag-input sentiment.

Sulfur and ammonia cost dynamics can transmit to global fertilizer pricing, though the article is company-specific.

Counterpoint

The apparent pricing power may be temporary if farmers continue cutting consumption, forcing future price concessions that would compress margins despite cost pass-through.

Key entities

  • AdvanSix

    NYSE-listed fertilizer/ammonia-related producer reporting Q2 results and outlining 2026 volume and capacity expansion plans.

  • USDA grant

    Management said it is applying for a USDA grant to expand ammonia capacity.

  • 45Q carbon capture tax credits

    Management cited 45Q credits as part of a stronger back-half 2026 cash-flow picture.

Related articles

$ASIXMed

AdvanSix Inc. Q2 2026 Earnings Call Summary

AdvanSix Inc. reported Q2 2026 sequential earnings improvement, citing raw material costs shifting from a $10 million headwind in Q1 to a $39 million tailwind in Q2, and fully offsetting $72 million in YoY raw material headwinds via pricing. It noted lower plant nutrient volumes, near-record domestic granular ammonium sulfate volumes, and expects sequential EBITDA and cash flow improvement in H2 2026.

$ASIXMed

AdvanSix Inc. (ASIX): Results of Operations and Financial Condition

AdvanSix Inc. (ASIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release ADVANSIX ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS 2Q26 Sales of $421 million, up 3% versus prior year 2Q26 Earnings Per Share of $0.12; Adjusted Earnings Per Share of $0.19 2Q26 Cash Flow from Operations of $10 million Parsippany, N.J., August 7,

$PLBLMed

Polibeli Group Ltd (PLBL): Financial results for H1 2026

Polibeli Group Ltd (PLBL) furnished an SEC Form 6-K — earnings release. Polibeli Group Ltd Announces Unaudited Financial Results for the six months ended June 30, 2026 On September 21, 2026, Polibeli Group Ltd (the “Company”) announced its unaudited financial results for the six months ended June 30, 2026. Business and Strategic Update ● As of the da

$VICRHighAI 8/10

Why is Vicor stock surging today?

Vicor Corporation's stock rose 12.3% after hours after raising its Q3 2026 revenue growth guidance from nearly 10% to over 20%, driven by royalties from its VPD licensing program. Four major companies have licensed the technology, and the CEO noted potential supply disruptions for unlicensed suppliers. The company also recently authorized a $150M share buyback and acquired properties for AI-driven demand. The Nasdaq closed at a record high, led by AI stocks, but broader indices were unchanged.

$OPTULow

Optimum Communications, Inc. (OPTU): Results of Operations and Financial Condition

Optimum Communications, Inc. (OPTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. The information appearing below under Item 4.02 regarding certain previously reported financial information of Optimum Communications, Inc. (the "Company") for the fiscal year ended December 31, 2025, and the fiscal quarter

$ABVXMedAI 8/10

EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.